Genmab A/SvsMerck & Company

GMAB and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Genmab A/S (GMAB) has a market value of $32.5B and Merck & Company (MRK) $331B. Over the last year, with dividends, GMAB moved +65.5% and MRK +44.8%. The P/E is 33.8 for GMAB and 134.8 for MRK. Dividend yield: GMAB none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GMAB$32.5B

    MRK$331B

    MRK is 10 times GMAB

  • Revenue, 12 months

    GMAB$3.7B

    MRK$67.4B

    MRK is 18 times GMAB

  • Net income, 12 months

    GMAB$963M

    MRK$2.5B

    MRK is 2.5 times GMAB

  • Operating margin

    GMAB28.6%

    MRK–

  • ROIC

    GMAB7.8%

    MRK3.9%

    3.9 points apart

  • P/E

    GMAB33.8

    MRK134.8

    MRK is 4.0 times GMAB

  • Dividend yield

    GMAB0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    GMAB+22.0%

    MRK+93.0%

    71.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GMAB+22.0%

MRK+93.0%

5010015020020222023202420252026
Returns by period
PeriodGMABWith dividendsMRKWith dividends
1 year since November 19, 2025+65.5%Price +65.5%+44.8%Price +40.7%
3 years since November 20, 2023+55.9%+15.9% a yearPrice +55.9%+42.7%+12.6% a yearPrice +30.2%
5 years since November 19, 2021+22.0%+4.1% a yearPrice +22.0%+93.0%+14.1% a yearPrice +65.7%
10 years since November 21, 2016+177.1%+10.7% a yearPrice +177.1%+205.2%+11.8% a yearPrice +124.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GMABGenmab A/SMRKMerck & Company

Valuation

GMABMRK
Valuation
Price$50.60$133.72
Market value$32.5B$331B
Enterprise value (EV)$35.9B$375B
P/E33.8134.8
P/E, 5-year median4.814.8
P/B5.67.4
EV/EBIT33.878.7
Free cash flow yield3.5%4.5%

Results and growth

GMABMRK
Results and growth
Revenue, 12 months$3.7B$67.4B
Net income, 12 months$963M$2.5B
Free cash flow, 12 months$1.1B$14.7B
Earnings per share, 12 months$1.54$0.98
Revenue growth, year on year19.2%1.3%
Revenue growth a year, past+24.8%over 2 years+9.4%over 5 years
EPS growth a year, past-51.7%over 2 years+21.2%over 5 years

Margins and returns on capital

GMABMRK
Margins and returns on capital
Gross margin93.6%71.8%
Operating margin28.6%–
Net margin25.9%3.6%
ROIC7.8%3.9%
ROE16.5%5.2%

Balance sheet

GMABMRK
Balance sheet
Cash$1.7B$9.7B
Total debt$5.2B$53.8B
Net debt / EBITDA–5.7
Interest cover4.0×2.4×

Dividends and buybacks

GMABMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield1.3%1.5%
Shareholder yield1.3%4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GMAB or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Genmab A/S or Merck & Company?

By market value, Merck & Company ($331B) is about 10.2 times Genmab A/S ($32.5B), at today's prices.

How did GMAB and MRK stock do over the last 10 years?

Since November 21, 2016, GMAB's price moved +177.1% and MRK's +124.9%. With dividends: GMAB +177.1% (+10.7% a year), MRK +205.2% (+11.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, GMAB or MRK?

The dividend yield at today's price is none for Genmab A/S and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of GMAB and MRK?

At today's price, the P/E is 33.8 for GMAB and 134.8 for MRK. The median of the last five years was 4.8 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Genmab A/S or Merck & Company?

Over the last twelve months, the net margin was 25.9% for Genmab A/S and 3.6% for Merck & Company, and the operating margin 28.6% and –. Revenue was $3.7B and $67.4B.

Which is the better investment, Genmab A/S or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.